



| | |
|-----------------------------------|---|
| Document | Guidelines on Euro-ataxia's Relationships with Industry |
| Owned by: | Euro-ataxia Secretary |
| Date of adoption by Board: | 11.03.2025 |
| Date last reviewed: | 11.03.2025 |

Euro-ataxia is funded by member organisations' subscriptions, contributions from partner organisations and sponsorship and grants from companies.

The following guidelines were adopted by the Euro-ataxia Board to manage its relationships with industry, and in particular pharmaceutical companies.

1. Euro-ataxia supports the development of new drugs and treatments for all ataxias and welcomes the investment of the pharmaceutical industry in this. The organisation aims to build strong relationships with companies involved in ataxia research and seeks to stay informed about the latest developments in the sector.
2. Euro-ataxia will maintain neutrality in all interactions with the pharmaceutical industry and will not promote or show favour to any specific manufacturer or product.
3. Euro-ataxia will not enter into any agreement which could threaten its non-profit status.
4. Personal data of members, donors or other confidential information about Euro-ataxia and its national associations shall remain the exclusive property of Euro-ataxia and its members and shall not be made available to any third party without their permission.
5. Euro-ataxia may accept donations, sponsorships and grants from pharmaceutical companies and other third parties. We will clearly acknowledge such funding.
6. In seeking sponsorship opportunities for an event or activity, Euro-ataxia will prioritise securing multiple sponsors.
7. When accepting sponsorship by pharmaceutical companies or other third parties, Euro-ataxia shall acknowledge this sponsorship by appropriate means. Under no circumstances will this acknowledgement include an advertisement for, or endorsement of, a product.
8. Sponsorship does not grant pharmaceutical companies and other third parties influence over the content of any publication or other information material produced by Euro-ataxia, nor does it entitle them to determine the programme or speakers at a



conference or symposium organised by Euro-ataxia. Euro-ataxia will retain complete editorial and managerial control at all times.

9. Euro-ataxia will from time to time, lend its support for the development of information material or awareness campaigns by pharmaceutical companies. However, it will not provide its support or logo for campaigns that promote or show favour to specific products.
10. Euro-ataxia will comply with all relevant legal and self-regulatory due-diligence procedures regarding funding from companies and provide accurate information to the best of its knowledge.
11. As per our Constitution, all representatives and voting members must declare any conflicts of interest, including but not limited to employment or consultancy for pharmaceutical companies or financial investments in pharmaceutical companies, which will be addressed as set out in the Constitution under section 11. Conflicts of Interest.
12. Euro-ataxia aims to foster collaborative partnerships with companies that prioritise the interests of patients and caregivers. It reserves the right to renegotiate or decline any funding that may compromise its independence.
13. These guidelines have been approved by the Euro-ataxia Board and are binding on Euro-ataxia. However, Euro-ataxia's member organisations may adopt their own regulations, provided they do not conflict with the principles outlined here. Euro-ataxia will not support events or publications by member organisations or other entities that fail to comply with these guidelines.
14. Euro-ataxia will refer to the EFPIA Code of Good Practice in relation to funding and our working relationships with the pharmaceutical industry.